MX2009004289A - Tricyclic compounds as matrix metalloproteinase inhibitors. - Google Patents

Tricyclic compounds as matrix metalloproteinase inhibitors.

Info

Publication number
MX2009004289A
MX2009004289A MX2009004289A MX2009004289A MX2009004289A MX 2009004289 A MX2009004289 A MX 2009004289A MX 2009004289 A MX2009004289 A MX 2009004289A MX 2009004289 A MX2009004289 A MX 2009004289A MX 2009004289 A MX2009004289 A MX 2009004289A
Authority
MX
Mexico
Prior art keywords
formula
matrix metalloproteinase
metalloproteinase inhibitors
tricyclic compounds
compounds
Prior art date
Application number
MX2009004289A
Other languages
Spanish (es)
Inventor
Tarek Mansour
Wei Li
Jianchang Li
Rajeev Hotchandani
Junjun Wu
Yuchuan Wu
Steve Tam
Joseph P Sypek
Iain Mcfayden
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of MX2009004289A publication Critical patent/MX2009004289A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/91—Dibenzofurans; Hydrogenated dibenzofurans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/76—Dibenzothiophenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Furan Compounds (AREA)

Abstract

The present invention relates to compositions of the formula (I): and pharmaceutically acceptable salts, hydrates, or esters thereof, wherein R1, R2, R3, R4, R5, X, and Y are as defined herein. The present teachings also provide methods of making the compounds of formula I, and methods of treating pathologic conditions or disorders mediated wholly or in part by matrix metalloproteinases, such as asthma and chronic obstructive pulmonary disease, comprising administering a therapeutically effective amount of a compound of formula (I) to a mammal (e.g., a human) in need thereof.
MX2009004289A 2006-10-27 2007-10-26 Tricyclic compounds as matrix metalloproteinase inhibitors. MX2009004289A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US85478606P 2006-10-27 2006-10-27
PCT/US2007/022651 WO2008057254A2 (en) 2006-10-27 2007-10-26 Tricyclic compounds as matrix metalloproteinase inhibitors

Publications (1)

Publication Number Publication Date
MX2009004289A true MX2009004289A (en) 2009-05-05

Family

ID=39166382

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009004289A MX2009004289A (en) 2006-10-27 2007-10-26 Tricyclic compounds as matrix metalloproteinase inhibitors.

Country Status (5)

Country Link
EP (1) EP2074107A2 (en)
JP (1) JP2010507674A (en)
CA (1) CA2667644A1 (en)
MX (1) MX2009004289A (en)
WO (1) WO2008057254A2 (en)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PA8779101A1 (en) * 2007-05-04 2008-12-18 Wyeth Corp "TRICYCLIC COMPOUNDS AS INHIBITORS OF MARRIAGE METALOPROTEINASES"
CA2747670A1 (en) 2008-12-19 2010-07-15 Bristol-Myers Squibb Company Carbazole carboxamide compounds useful as kinase inhibitors
US9273021B2 (en) 2009-02-05 2016-03-01 Trustees Of Boston College Dibenzofuran derivatives as inhibitors of fructose 1,6-bisphosphatase and methods of use thereof
FR2949463B1 (en) 2009-08-26 2011-09-16 Commissariat Energie Atomique MMP INHIBITORS
FR2996003B1 (en) 2012-09-25 2014-10-17 Commissariat Energie Atomique METHOD FOR SPECIFICALLY DETECTION IN SAMPLE MATRIX METALLOPROTEASE (MMP) OF INTEREST ONLY IN ACTIVE FORM
WO2014152115A1 (en) 2013-03-15 2014-09-25 Monsanto Technology Llc N-,c-disubstituted azoles for controlling nematode pests
US9981928B2 (en) 2013-06-20 2018-05-29 Bayer Cropscience Aktiengesellschaft Aryl sulfide derivatives and aryl sulfoxide derivatives as acaricides and insecticides
EP2907512A1 (en) 2014-02-14 2015-08-19 Commissariat A L'energie Atomique Et Aux Energies Alternatives Inhibitors of MMP-12 as antiviral Agents
MA52119A (en) 2015-10-19 2018-08-29 Ncyte Corp HETEROCYCLIC COMPOUNDS USED AS IMMUNOMODULATORS
SG11201804152RA (en) 2015-11-19 2018-06-28 Incyte Corp Heterocyclic compounds as immunomodulators
EP4292650A3 (en) 2015-12-22 2024-02-28 Incyte Corporation Heterocyclic compounds as immunomodulators
AR108396A1 (en) 2016-05-06 2018-08-15 Incyte Corp HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS
WO2017205464A1 (en) 2016-05-26 2017-11-30 Incyte Corporation Heterocyclic compounds as immunomodulators
KR102685249B1 (en) 2016-06-20 2024-07-17 인사이트 코포레이션 Heterocyclic Compounds as Immunomodulators
MA45669A (en) 2016-07-14 2019-05-22 Incyte Corp HETEROCYCLIC COMPOUNDS USED AS IMMUNOMODULATORS
US20180057486A1 (en) 2016-08-29 2018-03-01 Incyte Corporation Heterocyclic compounds as immunomodulators
US10042251B2 (en) 2016-09-30 2018-08-07 Rohm And Haas Electronic Materials Llc Zwitterionic photo-destroyable quenchers
WO2018119221A1 (en) 2016-12-22 2018-06-28 Incyte Corporation Pyridine derivatives as immunomodulators
US10308644B2 (en) 2016-12-22 2019-06-04 Incyte Corporation Heterocyclic compounds as immunomodulators
US20180179201A1 (en) 2016-12-22 2018-06-28 Incyte Corporation Heterocyclic compounds as immunomodulators
WO2019191707A1 (en) 2018-03-30 2019-10-03 Incyte Corporation Heterocyclic compounds as immunomodulators
DK3790877T3 (en) 2018-05-11 2023-04-24 Incyte Corp TETRAHYDRO-IMIDAZO[4,5-C]PYRIDINE DERIVATIVES AS PD-L1 IMMUNE MODULATORS
US11753406B2 (en) 2019-08-09 2023-09-12 Incyte Corporation Salts of a PD-1/PD-L1 inhibitor
KR20220075382A (en) 2019-09-30 2022-06-08 인사이트 코포레이션 Pyrido[3,2-d]pyrimidine compounds as immunomodulators
BR112022009031A2 (en) 2019-11-11 2022-10-11 Incyte Corp SALTS AND CRYSTALLINE FORMS OF A PD-1/PD-L1 INHIBITOR
AU2021373044A1 (en) 2020-11-06 2023-06-08 Incyte Corporation Process for making a pd-1/pd-l1 inhibitor and salts and crystalline forms thereof
TW202233615A (en) 2020-11-06 2022-09-01 美商英塞特公司 Crystalline form of a pd-1/pd-l1 inhibitor
WO2022099018A1 (en) 2020-11-06 2022-05-12 Incyte Corporation Process of preparing a pd-1/pd-l1 inhibitor

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3818549B2 (en) * 1996-01-11 2006-09-06 エーザイ株式会社 Fused tetracyclic heterocyclic derivatives
NZ333063A (en) * 1996-09-04 2000-12-22 Warner Lambert Co Dibenzofuran sulfonamide derivatives as matrix metalloproteinase inhibitors
KR20000068415A (en) * 1996-09-04 2000-11-25 로즈 암스트롱, 크리스틴 에이. 트러트웨인 Compounds for and a Method of Inhibiting Matrix Metalloproteinase
JPH11246527A (en) * 1998-03-02 1999-09-14 Shionogi & Co Ltd Mmp-8 inhibitor
MXPA01013172A (en) * 2001-02-14 2002-08-21 Warner Lambert Co Sulfonamide matrix metalloproteinase inhibitors.
PT1620429E (en) * 2003-04-11 2009-04-28 Glenmark Pharmaceuticals Sa Novel heterocyclic compounds useful for the treatment of inflammatory and allergic disorders: process for their preparation and pharmaceutical compositions containing them

Also Published As

Publication number Publication date
WO2008057254A2 (en) 2008-05-15
EP2074107A2 (en) 2009-07-01
JP2010507674A (en) 2010-03-11
WO2008057254A3 (en) 2009-01-08
CA2667644A1 (en) 2008-05-15

Similar Documents

Publication Publication Date Title
MX2009004289A (en) Tricyclic compounds as matrix metalloproteinase inhibitors.
MY154895A (en) Pyrimidine hydrazide compounds as pgds inhibitors
MY151172A (en) Pyrimidine amide compounds as pgds inhibitors
ATE537175T1 (en) NEW PIPERAZINO-DIHYDROTHIENOPYRIMIDINE DERIVATIVES
WO2006124692A3 (en) 3-cyanoquinoline inhibitors of tpl2 kinase and methods of making and using the same
EA200702339A1 (en) SUBSTITUTED AMIDA DERIVATIVES AS AN INHIBITOR PROTEINKINASE INHIBITORS
TW200616967A (en) Novel indazole carboxamides and their use
TW200728260A (en) Substituted-(quinazolinyl)phenyl thiophenyl-sulfonylureas, methods for making and intermediates thereof
EA200900178A1 (en) Condensed Heterocyclic Derivatives and Their Application
MX2009011749A (en) Tricyclic compounds as matrix metalloproteinase inhibitors.
MA35285B1 (en) indazoles
MX2011010964A (en) 4-azetidinyl-1-phenyl-cyclohexane antagonists of ccr2.
UA99361C2 (en) TRIAZINE COMPOUNDS AS PI3 KINASE AND mTOR INHIBITORS
TN2012000139A1 (en) Cgrp receptor antagonists
NO20091620L (en) Boronic acid and esters as inhibitors of fatty acid amide hydrolases
EA200970883A1 (en) INDOLKARBOXAMIDES AS IKK2 INHIBITORS
MX2012000488A (en) Combination therapy for the treatment of diabetes.
NZ591914A (en) Naphthylacetic acids
EA200800183A1 (en) NEW INDOLKARBOXAMID DERIVATIVES CONTAINING THEIR PHARMACEUTICAL COMPOSITION AND METHOD OF TREATMENT
MX2011010919A (en) 4-azetidinyl-1-heteroaryl-cyclohexane antagonists of ccr2.
NZ599099A (en) Phenyloxadiazole derivatives as pgds inhibitors
MX2011010963A (en) 4-azetidinyl-1-heteroatom linked-cyclohexane antagonists of ccr2.
TW200640905A (en) Monopotassium salt of an IκB kinase inhibitor
WO2009148600A8 (en) Deuterated lysine-based compounds
NO20081483L (en) Combination of compounds that can be used in the treatment of respiratory diseases, especially chronic obstructive pulmonary disease (COPD) and asthma

Legal Events

Date Code Title Description
HH Correction or change in general